Guggenheim analyst Vamil Divan assumed coverage of Amgen (AMGN) with a Neutral rating and $288 price target With the pending loss of U.S. market exclusivity for both Prolia and Xgeva later this month and the expected upcoming erosion for blockbuster medications such as Enbrel and Otezla, the firm views Amgen as a company with a portfolio that is “in transition,” but with “an intriguing pipeline of assets that could help to replace sales that are at risk,” the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMGN:
- Amgen price target lowered to $328 from $329 at Piper Sandler
- Biotech Alert: Searches spiking for these stocks today
- Cautious Hold on Amgen: Navigating Competitive Challenges and Market Potential for MariTide
- Amgen Stock May Get Fatter Premiums As It Slims Down Obesity Drug Competition with MariTide
- Uber downgraded, Rockwell Automation upgraded: Wall Street’s top analyst calls